ClinicalTrials.gg
CompletedNCT07024888Updated Jun 18, 2025

A Study Evaluating the Food Effect on the Pharmacokinetics of SSS17 Capsules in Chinese Healthy Subjects

A Phase 1 interventional study of SSS17 in Healthy Subjects (HS), sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD. (part of 3SBio Inc.) · Phase 1, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study mainly compared the blood drug concentration and main pharmacokinetic parameters of SSS17 capsules taken orally once by healthy Chinese subjects under fasting conditions, 2 hours after administration, and when consuming a high-fat meal or a low-fat meal simultaneously. The study evaluated the impact of food on SSS17 capsules.

02

Conditions studied

  • Healthy Subjects (HS)
03

In context

Lead sponsor

Shenyang Sunshine Pharmaceutical Co., LTD. is the lead sponsor of 40 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult subjects aged 18 to 45 years
  2. Good health status with no medical history.
  3. Agreement to use effective from signing ICF until 6 months after trial completion, with no reproductive plan.
  4. Voluntarily sign form (ICF), capable of protocol compliance and scheduled follow-up

Exclusion criteria

Exclusion Criteria:

  1. to drug/.
  2. Dysphagia, GI disorders affecting absorption, or relevant surgery history .
  3. Intolerance to venipuncture or needle/blood phobia.
  4. disorders affecting drug ADME.
  5. Clinically significant abnormalities in vital signs/PE/labs/12-lead /chest X-ray at screening.
  6. Family history of or major surgery within 3 months pre-screening.
  7. Participation in other drug/device trials with investigational product use within 3 months.
  8. Blood donation/loss within 3 months.
  9. Special diets (pitaya/grapefruit products) or strenuous exercise within 7 days pre-dosing affecting ADME.
  10. Any medication use within 14 days pre-dosing.
  11. Regular alcohol >14 units/week within 3 months.
  12. Smoking >5 cigarettes/day within 3 months or unwilling to abstain during trial.
  13. Caffeine products within 48h pre-dosing.
  14. Alcohol consumption within 48h or positive alcohol screen.
  15. Positive serology for , Ab, Ab, or syphilis.
  16. Pregnancy/lactation or unprotected sex
  17. Positive drug screen, drug abuse history, or drug use within 3 months.
  18. Any condition compromising safety/compliance, or investigator's judgment of unsuitability
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Other
    Fasting Group

    Drug: SSS17

  • Other
    Low-fat Meal Concomitant Administration Group

    Drug: SSS17

  • Other
    High-fat Meal 2-Hour Post-dose Group

    Drug: SSS17

Interventions

  • DrugSSS17

    Single oral administration of SSS17

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: Day1 to Day73

  2. AUC

    Time frame: Day 1 to Day 73

Secondary outcomes

  1. Tmax

    Time frame: Day1 to Day73

  2. t1/2

    Time frame: Day 1 to Day 73

  3. CL/F

    Time frame: Day 1 to Day 73

  4. AEs

    Time frame: up to Day 73

07

Study locations

1 site
  • The Affilated Hospital Of QingDao University
    Qingdao, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in May 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 17, 2025
StartActual
Mar 16, 2025
Primary completionActual
May 28, 2025
CompletionActual
May 28, 2025
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07024888
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Mar 16, 2025
Primary completion
May 28, 2025
Completion
May 28, 2025
Last update
Jun 18, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SSS17

Start the discussion